You are here
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg VirusSBC: Evrys Bio, LLC Topic: CBD18A002
In a pandemic or exposure to weaponized Marburg virus the morbidity, mortality and social unrest that will ensue before vaccines orMilitary operating on foreign soil as well as to the population of the US Homeland. Practically all threat agents of biological origin (except forcertain non-proteinaceous toxins, typically produced by marine organisms and fungi) have their structure and vital function ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense
SBC: SIGNATURE RESEARCH, INC. Topic: 1
Signature Research, Inc. (SGR) and Michigan Technological University (MTU) propose a Phase I STTR effort to develop a learning algorithm which exploits the spatio-spectral characteristics inherent within IR imagery and motion imagery.Our archive of modelled and labeled data sets will allow our team to thoroughly capture the variable elements that will drive machine learning performance.The overall ...STTR Phase I 2018 Department of DefenseNational Geospatial-Intelligence Agency
SBC: Luna Innovations Incorporated Topic: CBD18A002
Marburg virus (MARV) is a filamentous enveloped non-segmented negative sense RNA virus. This viruse is considered to be extremelydangerous with case fatality rates as high as 88-90%. Extensive efforts have gone towards effective vaccines for MARV prevention, however,none have been successfully established as licensed vaccines. Glycoprotein (GP) is the only surface protein of MARV. There are substa ...STTR Phase I 2018 Department of DefenseOffice for Chemical and Biological Defense